Notably, Kyriakidou et al. provided direct pharmacogenetic evidence that the GLP1R coding variant rs367543060, along with additional variants in TCF7L2 and CTRB1/2, predicts variable glycaemic responses to GLP-1RAs among T2DM patients [75]. This evidence concerns the gene TCF7L2 and type 2 diabetes mellitus.